Goldman-backed Aragen eyes Rs 12,000 crore as pre-IPO dose; Novo Nordisk keen

Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a minority stake and engaged in early discussions, they said. In February, Novo Holdings, the holding company of Novo Nordisk, acquired US-based publicly-listed contract development and manufacturing organisation Catalent for $16.5 billion.